Download Free Sample
Buy Now
Global mRNA Synthesis and Manufacturing Market Overview
The mRNA synthesis and manufacturing market is estimated to be USD 0.56 billion in 2026. It is expected to reach USD 4.20 billion by 2035, representing a CAGR of 40.9% between 2028 and 2035.
See What’s in the Full Report – Request Your Complimentary Insights!
Ribonucleic acid (RNA) is a molecule which is present in all living cells and translates genetic information to various proteins in order to perform several cellular processes. Notably, RNA can be of different types, including messenger RNA (mRNA), transfer RNA (tRNA) and ribosomal RNA (rRNA); of these, mRNA has emerged as one of the key therapeutic modalities in the modern healthcare industry.
mRNA is a single-stranded molecule, which carries the genetic information present in the DNA to produce proteins. The genetic coding which is present on mRNA gets translated into amino acids; these amino acids get further processed into a functional product (proteins).
 |
 |
 |
Notably, post COVID-19 pandemic, mRNA vaccine and therapeutics manufacturing have garnered significant attention as they have evolved as a next generation drug class for the treatment of COVID-19. Further, mRNA therapeutics are also being evaluated for the treatment of various oncological, infectious, and genetic disorders. This versatility and scalability of mRNA therapeutics have further contributed to their adoption, positioning them as a cornerstone of personalized mRNA medicine production and vaccine development. In addition, these therapeutics are likely to have an improved safety profiles for patients as there is minimal risk of insertional mutagenesis.
 |
 |
 |
Owing to this success, the demand for mRNA synthesis and manufacturing has increased significantly, prompting mRNA therapeutic / vaccine developers to actively explore avenues that enable them to meet the existing demand. In this context, outsourcing emerged as a lucrative option for mRNA therapeutic / vaccine development companies, offering efficient and scalable solutions for mRNA therapeutics and vaccine development.
 |
 |
 |
Considering the prevalent trends and projected opportunity associated within the overall mRNA synthesis and manufacturing domain, we believe that the domain is likely to witness single-digit market growth in the foreseen future.
mRNA Synthesis and Manufacturing Market: Report Attributes
| Key Report Attributes | Details | |
| Historical Trend | Since 2021 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | $ 0.56 Billion | |
| Market Size 2035 | $ 4.20 Billion | |
| CAGR (2028-2035) | 40.9% | |
The mRNA synthesis and manufacturing market analysis also features the likely distribution of the current and forecasted opportunity within the mRNA synthesis and manufacturing domain across various segments, such as type of product, scale of operation, synthesis and manufacturing activity, indication type, therapeutic area, application area and geographical regions.
We have created three market forecast scenarios, conservative, base and optimistic, to account for future uncertainties in key parameters and enhance the robustness of our model. These scenarios represent different tracks of the industry's evolution.
The rising incidence of chronic diseases, increasing need for technical expertise in the domain and development of advanced mRNA technologies have spurred the need for outsourcing mRNA synthesis and manufacturing activities. Additionally, the use of artificial intelligence / AI in drug discovery has significantly helped the stakeholders to develop more accurate, treatment specific mRNAs for therapeutics and vaccines.
Recent Developments in mRNA Synthesis and Manufacturing Market
Several recent developments in the field of mRNA synthesis and manufacturing have occurred, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall mRNA synthesis and manufacturing market trends detailed in our analysis.
- In July 2025, Wacker Chemie opened its new Wacker Biotechnology Center in Munich, Germany, to accelerate the development of biopharmaceutical manufacturing processes for proteins and nucleic acids.
- In June 2025, Ethris entered into a collaboration with Thermo Fisher Scientific, combining the former company’s comprehensive mRNA technology platforms with Thermo Fisher’s manufacturing capabilities, with an aim to advance mRNA therapeutics from research to clinical stages.
- In June 2025, TriLink BioTechnologies signed a partnership agreement with Quantoom Biosciences to access former company’s CleanCap® mRNA capping technology and accelerate the overall mRNA production processes.
mRNA Synthesis and Manufacturing Market Segmentation Insights
The market research report presents an in-depth analysis of the various mRNA synthesis and manufacturing companies, across different segments, as defined in the table below:
mRNA Synthesis and Manufacturing Market: Market Segmentation
| Market Segmentation | Details | |
| Type of Product |
|
|
| Scale of Operation |
|
|
| Synthesis and Manufacturing Activity |
|
|
| Indication Type |
|
|
| Therapeutic Area |
|
|
| Application Area |
|
|
| Geographical Regions |
|
|
| Market in North America |
|
|
| Market in Europe |
|
|
| Market in Asia-Pacific |
|
|
| Market in Latin America |
|
|
| Market in Middle East and North Africa |
|
|
Pay Only for What You Need – The Best Way to Optimize
The growing demand for mRNA as a drug agent, lack of manufacturing capabilities and the need for independent geographical mRNA therapeutics supply chain has prompted the mRNA drug production market players to outsource various operations involved in mRNA synthesis.
Industry Experts on mRNA Manufacturing Industry Outlook
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:
- Chief Executive Officer, Mid-sized Organization, Belgium
- Chief Commercial Officer, Mid-sized Organization, France
- Business Development Manager, Mid-sized Organization, Spain
- Team Leader, Large Organization, South Korea
In addition, the market report includes transcripts of the following other third-party discussions:
- Scientist in Nucleic Acid Therapeutics, Very Large Organization, United States
- Senior Product Manager, Very Large Organization, United States
- NEB RNA Research Senior Scientist, Large Organization, United States
- Professor and Director of the BASE facility and, Associate Professor and Deputy Director of the BASE facility, Vert Large Organization, Australia
mRNA synthesis and manufacturing domain will mark a turning point in 2025. Team Leader of a large organization in South Korea states, “More than 90% of the companies prefer to outsource the mRNA manufacturing operations to third party service providers.”
mRNA Synthesis and Manufacturing Market Share Insights
Market Share by Type of Product: Active Pharmaceutical Ingredients Sub-segment Holds the Largest Market Share
According to our projections, in 2026, the active pharmaceutical ingredients sub-segment is likely to capture majority (>60%) of the mRNA synthesis and manufacturing market share.
This is due to the fact that active pharmaceutical ingredients serve as a fundamental component of any therapeutic / vaccine, thereby affecting the overall efficacy and safety of the product.
Market Share by Scale of Operation: Commercial Scale Sub-segment Hold the Largest Market Share
In the current year, commercial scale sub-segment occupies the highest market share (>85%) as per mRNA synthesis and manufacturing market report, given the fact that a large number of mRNA-based therapeutics and vaccines are currently commercialized.
Further, the market for preclinical and clinical scale is likely to witness a moderate increase, growing at a CAGR of 3.4% during the forecast period. Extensive research and development in this domain are fueling the growth in preclinical and clinical sector, due to which a rapid increase in the development of mRNA-based products has been witnessed. Moreover, the companies are focused on scale-up of mRNA manufacturing facilities to support operations across various scales.
Market Share by Synthesis and Manufacturing Activities: Contract Manufacturing Sub-segment Dominates the Market
Currently, the contract manufacturing sub-segment occupies the highest market share (~60%) as per our market report. This dominance is primarily driven by the complexity of mRNA production, which demands specialized expertise and often relies on third-party service providers.
Further, the market is likely to witness a substantial increase in the share of in-house manufacturing sub-segment, growing at a CAGR of 7.5% during the forecast period. This is because of growing emphasis on the safety and efficacy of mRNA-based therapeutics, which is encouraging researchers and drug developers to strengthen their in-house capabilities for producing high-quality mRNA.
Market Share by Indication Type: COVID-Indication Sub-segment Holds the Largest Share
In the current year, the COVID indication sub-segment occupies the highest market share (95%) as per mRNA synthesis and manufacturing market analysis. This is due to the fact that mRNA-based products can instruct cells to produce specific pathogen proteins, which in turn trigger a strong and targeted immune response without exposing the individual to the actual pathogen.
Further, the market is likely to witness a substantial increase in the share of non-COVID indications, growing at a CAGR of 37.5% during the forecast period. This is a result of several advancements that are being made in this domain to develop mRNA-based products for other therapeutic indications, including oncological disorders, rare disorders and genetic disorders.
Market Share by Therapeutic Area: Focus on Infectious Disease mRNA therapies
In 2026, the infectious diseases sub-segment occupies the highest market share (~95%), given the fact that mRNA therapeutics and vaccines showcased significant success in combating the COVID-19 pandemic.
Further, the market is likely to witness a significant oncology mRNA therapy manufacturing, with 60.7% mRNA synthesis and manufacturing market growth, owing to the increasing prevalence of cancer and a dire need to develop novel therapeutic options to treat oncological disorders efficiently.
Market Share by Application Area: mRNA Vaccines Sub-segment Holds the Largest Share
In 2026, the market is anticipated to be solely driven by mRNA vaccines sub-segment as per mRNA synthesis and manufacturing market forecast, given their proven clinical success, broad preventive applications and flexible nature.
Further, the market is likely to witness a substantial increase in the share of mRNA therapeutics, growing at a CAGR of 61.1% during the forecast period. This is because of their rapidly expanding therapeutic applications for therapeutic areas such as oncological, genetic, autoimmune and cardiovascular disorders, thus generating a strong clinical momentum for mRNA therapeutics.
Your Business is Unique – Why Shouldn’t Your Report Be?
Market Share by Geographical Regions: North America to Propel in the mRNA Synthesis and Manufacturing Sector in the Coming Years
As per our mRNA synthesis and manufacturing market trends, North America is likely to capture majority share (>40%) of the market. Furthermore, the market in North America is expected to grow at a CAGR of 6.6%, during the forecast period.
This is because of the advanced healthcare infrastructure in North America, enabling several players in the industry to conduct extensive research and develop novel mRNA modalities for a wide array of therapeutic indications.
mRNA Synthesis and Manufacturing Market: Report Deliverables
| Report Deliverables | Details | |
| Excel Data Packs (Complimentary) |
|
|
| Key mRNA Synthesis and Manufacturing Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) | Available | |
| Customization Scope | 15% Free Customization | |
mRNA Synthesis and Manufacturing Market Key Takeaways
The “mRNA Synthesis and Manufacturing Market (4th Edition): Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape of mRNA custom synthesis service providers, mRNA contract manufacturing service providers and mRNA synthesis kits along with their respective company competitiveness and product competitiveness analyses, partnerships and collaborations, likely partner analysis, big player initiatives and market size and future opportunities within the mRNA synthesis and manufacturing industry.
mRNA Market Competitive Landscape: mRNA Custom Synthesis Service Providers
Presently, close to 55 service providers are engaged in offering services for custom synthesis of mRNA. Of these, close to 40% of the companies have been established post-2011 indicating the growing interest of stakeholders in this domain. Notable examples of companies (established post- 2011, in alphabetical order) include APExBIO, BASE Facility, Click Biosystems and YXgene.
Further, about 60% of the players are headquartered in North America, given the more favorable and streamlined regulatory environment related to the approval of drugs across the region, allowing companies to operate with fewer barriers, compared to other regions.
Want Information on Specific Region / Segment?
Competitive Landscape of mRNA Contract Manufacturing Service Providers
The mRNA contract manufacturing service providers landscape features close to 45 players having expertise in providing contract services for the synthesis and manufacturing of mRNA. The market landscape is well-fragmented, featuring the presence of small, mid-sized, large, and very large companies.
Interestingly, majority (~60%) of the players offer manufacturing services for both drug substance and drug product. This integrated approach streamlines the overall drug development and manufacturing process for the clients, thereby reducing the risk of unwanted impurities and inconsistencies.
Market Size Analysis: What is the Opportunity for the mRNA Synthesis and Manufacturing?
The global mRNA synthesis and manufacturing market size is around $ 0.56 billion in 2026. In terms of the scale of operation, commercial scale sub-segment holds the largest share of the overall market owing to the fact that currently, a large number of mRNA therapeutics and vaccines are receiving regulatory approvals.
Further, the market size for preclinical and clinical scale is likely to grow at a relatively higher CAGR of 3.4% during the forecast period. The ability for mRNA therapeutics and vaccines to effectively target a wide array of disorders is targeting the growth of this sub-segment.
Regional Analysis: Which Region Holds the Largest mRNA Synthesis and Manufacturing Market Share?
North America is Leading the Market
North American companies are likely to dominate the market in 2035, owing to the robust research and development activities, coupled with the increasing adoption of mRNA therapeutics and growing mRNA vaccine manufacturing market trends within this region. Further, this trend is unlikely to change during the forecast period, with the market in North America growing at a higher CAGR of 6.6%.
What are the Key Drivers of mRNA Synthesis and Manufacturing Market?
The market is experiencing steady growth, primarily driven by the increasing extent of outsourcing in this domain owing to the growing need for specialized expertise, scalable production process, and robust infrastructure. Additionally, the rapid expansion of therapeutic applications, driven by the adaptability of mRNA technology and their potential to produce any protein in vivo and in vitro has accelerated the market growth.
Key Market Trends in mRNA Synthesis and Manufacturing Market
Rising Partnerships and Collaborations Amongst the mRNA Synthesis and Manufacturing Companies to Foster Progress and Innovation in Expanding their Capabilities
Players engaged in the mRNA synthesis and manufacturing domain have forged several partnerships with other stakeholders to enhance their respective service and kit portfolios. Close to 50% of the partnerships in this domain were inked in the last three years. Both international and local stakeholders have signed numerous agreements focused on mRNA synthesis and manufacturing across various regions; however, the activity was observed to be primarily concentrated in the US.
Increase in Big Player Initiatives Reflects the Rising Interest of Companies in mRNA Synthesis and Manufacturing
Big players in this domain have strategically entered into several partnerships, acquired other firms, raised several fundings and expanded their capabilities in order to stay at the forefront of this domain. Notably, close to 20% of the initiatives in this domain were undertaken in the last two years. Of these, maximum initiatives were undertaken by big players in the year 2022; this is because of the increased demand of mRNA for production of COVID-related vaccines and therapeutics. Moreover, the players are meticulously focused on complying with the regulatory landscape for mRNA production.
mRNA Synthesis and Manufacturing Market Report Coverage
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the mRNA synthesis and manufacturing industry, across different geographies. Amongst other elements, the market report includes:
- An Infographic Executive Summary
- Market Landscape of mRNA Custom Synthesis Service Providers
- Company Competitiveness Analysis of mRNA Custom Synthesis Service Providers
- Market Landscape of mRNA Contract Manufacturing Service Providers
- Company Competitiveness Analysis of mRNA Contract Manufacturing Service Providers
- Market Landscape of mRNA Synthesis Kits
- Product Competitiveness Analysis of mRNA Synthesis Kits
- Partnerships and Collaborations
- Likely Partner Analysis
- Big Pharma Initiatives
- Market Forecast and Opportunity Analysis
